ErbB receptor tyrosine kinase inhibitors (EGFR-TKIs), often used in cancer chemotherapy, can inhibit EGFR signaling in intestinal epithelial cells and decrease the capacity for growth and repair of the intestinal epithelium, which will result in atrophy of intestinal mucosa and secretory diarrhea [41]. This evidence concerns the gene EGFR and cancer.